LaFleur & Godfrey LLC Reduces Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

LaFleur & Godfrey LLC reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 36.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,339 shares of the medical device company’s stock after selling 1,905 shares during the period. LaFleur & Godfrey LLC’s holdings in DexCom were worth $224,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of DXCM. Vanguard Group Inc. increased its holdings in shares of DexCom by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock worth $6,186,539,000 after buying an additional 136,282 shares during the last quarter. Blair William & Co. IL increased its stake in DexCom by 1.4% during the first quarter. Blair William & Co. IL now owns 4,532,687 shares of the medical device company’s stock worth $628,684,000 after acquiring an additional 64,683 shares during the last quarter. Legal & General Group Plc raised its position in DexCom by 1.7% in the second quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock valued at $339,352,000 after purchasing an additional 49,076 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in shares of DexCom by 16.9% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock valued at $276,538,000 after purchasing an additional 353,019 shares during the last quarter. Finally, 1832 Asset Management L.P. lifted its position in DexCom by 1.1% in the first quarter. 1832 Asset Management L.P. now owns 1,823,400 shares of the medical device company’s stock valued at $252,906,000 after buying an additional 20,400 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Performance

DXCM traded up $1.80 on Wednesday, reaching $68.90. The company had a trading volume of 2,001,062 shares, compared to its average volume of 3,816,600. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The stock has a market capitalization of $27.40 billion, a PE ratio of 43.29, a P/E/G ratio of 2.16 and a beta of 1.18. The stock has a 50-day moving average price of $69.94 and a 200-day moving average price of $101.37.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.04. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.34 EPS. As a group, research analysts forecast that DexCom, Inc. will post 1.69 EPS for the current fiscal year.

Analyst Ratings Changes

DXCM has been the subject of a number of research analyst reports. Robert W. Baird raised their target price on DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a report on Monday, August 5th. Stifel Nicolaus boosted their target price on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, August 23rd. UBS Group cut their price target on DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a report on Friday, July 26th. Morgan Stanley decreased their price objective on DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a research note on Friday, July 26th. Finally, Wells Fargo & Company cut their target price on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating on the stock in a research note on Friday, July 26th. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $110.69.

Insider Activity

In related news, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,824 shares of company stock valued at $126,390 in the last ninety days. 0.30% of the stock is currently owned by company insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.